AUTH/3705/11/22 - Complainant v AbbVie

Allegations about the dosing information for Rinvoq on AbbVie’s website

  • Received
    14 November 2022
  • Case number
  • Applicable Code year
  • Completed
    20 November 2023
  • No breach Clause(s)
  • Additional sanctions
  • Appeal
    No appeal

Case Summary

This case was in relation to dosing information about Rinvoq on AbbVie’s product website.

The Panel ruled no breach of the following Clauses of the 2021 Code, as the Panel did not consider that within the context of the discrete section of the webpage, that the claim at issue misleadingly implied that Rinvoq could be taken with any type of food, including grapefruit, as alleged. The Panel considered that the claim in question was capable of substantiation, and did not consider that the complainant had demonstrated that AbbVie had failed to maintain high standards, or consequently brought discredit upon, or reduced confidence in, the pharmaceutical industry.

No Breach of Clause 2

Requirement that activities or materials must not bring discredit upon, or reduce confidence in, the pharmaceutical industry

No Breach of Clause 5.1

Requirement to maintain high standards

No Breach of Clause 6.1

Requirement that information, claims and comparisons must not be misleading

No Breach of Clause 6.2

Requirement that information, claims and comparisons must be capable of substantiation

This summary is not intended to be read in isolation.
For full details, please see the full case report below.